JournalsHub
.online
Find My Journal
BL

Brian Leyland‐Jones

Avera Health US

ORCID iD 0000-0003-2434-0774
442
Publications
32,142
Citations
65
H-Index
164
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

441 total

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study PDF

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederlé, Michael E. Hahn et al. - Nature Medicine, 2019
Cited by 706 OpenAlex

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial PDF

David Cameron, Martine Piccart, Richard D. Gelber, Marion Procter, Aron Goldhirsch et al. - The Lancet, 2017
Cited by 1,022 OpenAlex

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500 PDF

Jeffrey B. Smerage, William E. Barlow, Gabriel N. Hortobágyi, Eric P. Winer, Brian Leyland‐Jones et al. - Journal of Clinical Oncology, 2014
Cited by 642 OpenAlex

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart, Evandro de Azambuja, Marion Procter et al. - The Lancet, 2013
Cited by 501 OpenAlex

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

Mary Jo Lund, Katrina F. Trivers, Peggy L. Porter, Ralph J. Coates, Brian Leyland‐Jones et al. - Breast Cancer Research and Treatment, 2008
Cited by 396 OpenAlex

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu et al. - Journal of Clinical Oncology, 2006
Cited by 484 OpenAlex

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer PDF

Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch et al. - New England Journal of Medicine, 2005
Cited by 5,082 OpenAlex

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study PDF

Brian Leyland‐Jones, Semiglazov Vf, Marek Pawlicki, Tadeusz Pieńkowski, Sergei Tjulandin et al. - Journal of Clinical Oncology, 2005
Cited by 664 OpenAlex

Breast cancer trial with erythropoietin terminated unexpectedly

Brian Leyland‐Jones - The Lancet Oncology, 2003
Cited by 472 OpenAlex

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 PDF

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton et al. - New England Journal of Medicine, 2001
Cited by 11,464 OpenAlex

Research Topics

HER2/EGFR in Cancer Research (85) Cancer Genomics and Diagnostics (82) Cancer Treatment and Pharmacology (49) PI3K/AKT/mTOR signaling in cancer (47) Breast Cancer Treatment Studies (45)

Affiliations

AstraZeneca (United Kingdom)
GB 2018 - 2018
University of Southern California
US 2013 - 2013
Roche (Switzerland)
CH 2016 - 2012
University of Maryland, Baltimore
US 2006 - 2006
National Academy of Medicine
US 2011 - 2011

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now